European Commission Grants Conditional Approval for Spinal Muscular Atrophy Treatment
Zolgensma, a gene therapy for spinal muscular atrophy (SMA), has recently been granted conditional approval by the European Commission (EC). This is extremely exciting news for those living with SMA…